loading

INVITRO INTERNATIONAL SIGNS MERGER LETTER OF INTENT

IRVINE, CA, March 3, 1997 — InVitro International (Nasdaq SmallCap Market Symbol “INVI”) today announced it has signed a letter of intent to merge with Shenyang International Inc. in a transaction where InVitro stockholders would retain 20% of the combined company’s common stock. The proposed transaction is subject, among other conditions, to additional due diligence investigations, approval by the board of directors for each of the parties, preparation and execution of a definitive merger agreement, filing and the effectiveness of a registration statement and proxy materials with the Securities and Exchange Commission, and approval by the majority vote of InVitro shareholders.

The Company currently anticipates the merger proposal will be presented to InVitro’s board for consideration before the end of March 1997.

Privately-held Shenyang International Inc. is a foreign holding company organized in the British Virgin Islands and owns 99% of ShenYang Holding Company (“SHC”). Organized in 1988 and based in the Liaoning Province of northeastern China, SHC operates four business divisions in mainland China with approximately 300 employees. SHC’s business operations include distribution of medical products, the manufacture and sale of computer systems, ownership and management of the Lan Hua Hotel in ShenYang city and development of international industrial trade. Among other products, SHC distributes medical scanning devices for General Electric and markets personal computer hardware and networking systems. SHC has operated profitably for the last five years, and its annual revenues have increased from $6.5 million in 1992 to more than $15 million currently.

InVitro International, organized in 1985, develops and markets proprietary in vitro assay systems to detect, predict and rank potential irritation and toxic levels of substances to humans and the environment and distributes child safety and identification products. Located in Irvine, California, the Company distributes its products throughout North America, Europe and the Pacific Rim. InVitro previously reported a net loss for the year ended September 30, 1996 of $1,899,000, or $.15 per share, on revenues of $1,063,000. Results for the most recent fiscal quarter ended December 31, 1996 were a net loss of $506,000, or $.04 per share, on $259,000 in net sales. At February 28, 1997, InVitro had 14,028,300 shares of common stock outstanding.

Assuming the proposed merger is successfully completed, InVitro has undertaken to reduce its existing business operations to eliminate negative cash flow and currently anticipates those operations will continue under the direction of InVitro’s management as a separate division or subsidiary of the combined enterprise.

The statements made in this press release contain certain forward looking statements within the meaning of section 27a of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934 that involve a number of risks and uncertainties, including the risk that InVitro may be unable to complete the proposed transaction. Actual events or results may differ from InVitro’s expectations. In addition, investors should be apprised of risk factors discussed from time to time in the Company’s filings with the Securities and Exchange Commission, including without limitation information set forth in Exhibit 99.1 filed with the Company’s Annual Report on Form 10-KSB for the fiscal year ended September 30, 1996.

INVITRO INTERNATIONAL REPORTS FIRST QUARTER RESULTS

Board Of Directors Defer Decision To Implement 1-For-10 Reverse Stock Split Recently Approved By Shareholders
IRVINE, CA, February 4, 1997 — InVitro International (NASDAQ Small Cap; INVI) today reported results for its first quarter ended December 31, 1996. Revenues for the quarter were $259,000 compared to $225,000 for the first quarter of the prior year, a 15% increase. The net loss for the current quarter was $506,000 or $.04 per share, compared to a net loss of $522,000 or $.04 per share reported for the same period of the previous year.

During its Annual Shareholders Meeting held on Friday, January 31, 1997, the Company also announced its Board will delay a decision whether and when to implement a 1-for-10 reverse stock split authorized at the meeting by a majority of shareholders. InVitro International’s Board of Directors will defer an implementation decision until the timing of revised NASDAQ rules are announced and the Board has had an opportunity to assess initial results from the GiftPax program for Guardian DNA. (Guardian DNA is the new three-part infant/child safety system being marketed directly to 3.7 million new mothers during calendar year 1997 via GiftPax/American Sampling, Inc.) “We should have a preliminary indication as to the level of sales we can expect from the GiftPax opportunity by the end of March,” stated W. Richard Ulmer, President and CEO for InVitro International.

InVitro International is engaged in the development, manufacture and sale of quality, proprietary preventive products and services to ensure the safekeeping of humans and the environment, and to minimize animal testing in commercial and academic enterprise.

Except for the historical information contained herein, the matters discussed in this news release are forward looking statements that involve risks and uncertainties, including the acceptance of new products, the impact of competitive products and pricing, and the management of growth. Please refer to the Company’s filings with the Securities and Exchange Commission for a summary of cautionary statements.

INVITRO INTERNATIONAL TO REACH NEARLY 4 MILLION NEW MOTHERS IN 1997 WITH GUARDIAN DNA

$1.8 Million In INVI Sales To Result From Every 1 Percent Who Decide To Buy
IRVINE, CA, December 18, 1996 — InVitro International (NASDAQ Small Cap; INVI) today reported results of operations for its fiscal year ended September 30, 1996. The net loss for fiscal 1996 was $1,899,000 ($0.15 per share) on revenues of $1,063,000 versus a net loss of $2,763,000 ($0.23 per share) on revenues of $1,137,000 in fiscal 1995, and is the lowest in the Company’s public history. Progress with regard to net financial results are attributable to cost controls implemented throughout the fiscal year, while maintaining fiscal 1995 sales levels.

President and CEO for InVitro International, W. Richard Ulmer stated “We are encouraged that annual sales remained virtually the same and that losses declined by nearly $1 million, despite the heavy fourth quarter investment to introduce Guardian DNAä, the new infant/child safety system. We remain enthusiastic regarding future prospects for Guardian and are pleased that our core technology has recently attracted several new and important customers, including Ingman Laboratories in Minneapolis, Minnesota and Sima-Labs International in Merrillville, Indiana. Additionally, InVitro recently installed its IrritectionÒ Assay System in two textile companies, one of which carries world-wide name recognition.”

The goal of Company-wide profitability previously forecasted for InVitro’s first quarter of fiscal 1997 will not be met. The delay is a function of the difficulty in predicting the timing and the level of acceptance for Guardian DNA. As reported earlier, the Company has teamed with GiftPax/American Sampling, Inc. to provide approximately 3.7 million new mothers during 1997 with information about Guardian DNA during their hospital stay and the ability to purchase it at a reduced price. The first shipment of redeemable Guardian brochures were delivered to hospitals nationwide in early December and the product fulfillment center is ready to begin processing orders. “We feel extremely confident that Guardian DNA will be a success as it reaches hundreds of thousands of new mothers in January, and each successive month throughout 1997,”remarked Ulmer. “We estimate that a mere 1% response rate over the course of the next 12 months will turn the corner for the Company financially. Given the positive acceptance levels predicted by internal market research among end users, we have every reason to remain excited.”

InVitro International is engaged in the development, manufacture and sale of quality, proprietary preventive products and services to ensure the safekeeping of humans and the environment, and to minimize animal testing in commercial and academic enterprise.

Except for the historical information contained herein, the matters discussed in this news release are forward looking statements that involve risks and uncertainties, including the acceptance of new products, the impact of competitive products and pricing, and the management of growth. Please refer to the Company’s filings with the Securities and Exchange Commission for a summary of cautionary statements.